HomeAI · summaries
Storia in 2 fonti
A COPD drug from China draws $115M in venture funding
Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
A COPD drug from China draws $115M in venture funding
Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development…
- ·
endpoints.news
Expedition gets another $115M for its twist on China NewCo model
Expedition Therapeutics disclosed the Series B in conjunction with dosing the first patient in its global Phase 2 for the DPP1 inhibitor it licensed from Fosun Pharma.